Pediatric Blood and Cancer

Journal

Publication Venue For

  • Location of death and hospice use in children with cancer varies by type of health insurance.  69. 2022
  • Comment on: Patients with nonmetastatic embryonal rhabdomyosarcoma arising in the biliary tract should be treated on low-risk clinical trials.  69. 2022
  • Obesity in children with acute promyelocytic leukemia: What is its prevalence and prognostic significance?.  69. 2022
  • SARS-CoV-2 vaccine acceptability among caregivers of childhood cancer survivors.  69. 2022
  • Adverse childhood experiences in children and adolescents with sickle cell disease: A retrospective cohort study.  69. 2022
  • Altered mental status as a presentation of rhabdomyolysis in a patient with sickle cell anemia.  69. 2022
  • Bloom where you are planted: Hemangioma or malignancy?.  69. 2022
  • Use of infusion ports in patients with sickle cell disease: Indications and complications.  69. 2022
  • A randomized double-blind placebo-controlled trial of the effectiveness of melatonin on neurocognition and sleep in survivors of childhood cancer.  69. 2022
  • BRAF mutation in neuroblastoma: A rare finding 2022
  • Consensus definition of essential, optimal, and suggested components of a pediatric sickle cell disease center 2022
  • Cytarabine dose reduction in patients with low-risk acute myeloid leukemia: A report from the Children's Oncology Group..  69:e29313. 2022
  • Filgrastim desensitization in a patient with Hodgkin lymphoma.  69. 2022
  • Impact of telehealth visits on hydroxyurea response in sickle cell anemia.  68. 2021
  • Multi-institutional analysis of treatment modalities in basal ganglia and thalamic germinoma.  68. 2021
  • PediCARE: Development of a poverty-targeted intervention for pediatric cancer.  68. 2021
  • The ASH-ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question.  68. 2021
  • Impact of location of inpatient cancer care on patients with Ewing sarcoma and osteosarcoma—A population-based study.  68. 2021
  • Effect of COVID-19 on anakinra-induced remission in homozygous STX11 hemophagocytosis lymphohistiocytosis.  68. 2021
  • Acute chest syndrome in pediatric sickle cell disease: Associations with racial composition and neighborhood deprivation.  68. 2021
  • Impacts of COVID-19 on caregivers of childhood cancer survivors.  68. 2021
  • Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group.  68. 2021
  • Suboptimal outcome for patients with biliary rhabdomyosarcoma treated on low-risk clinical trials: A report from the Children's Oncology Group.  68. 2021
  • Visual outcomes following everolimus targeted therapy for neurofibromatosis type 1-associated optic pathway gliomas in children.  68. 2021
  • Practice patterns for neuroimaging and transfusion therapy for management of neurologic complications in sickle cell anemia: DISPLACE consortium.  67. 2020
  • The use of anakinra in the treatment of secondary hemophagocytic lymphohistiocytosis.  67. 2020
  • Outpatient pain clinic and intranasal fentanyl to improve sickle cell disease outcomes.  67. 2020
  • Integrative genomic analysis of B-lymphoblastic lymphoma with intrachromosomal amplification of chromosome 21.  67. 2020
  • Cardiac autonomic dysfunction in survivors of childhood acute lymphoblastic leukemia: The St. Jude Lifetime Cohort Study.  67. 2020
  • Do children and adolescents with completely resected alveolar rhabdomyosarcoma require adjuvant radiation? A report from the Children's Oncology Group.  67. 2020
  • Practice patterns for stroke prevention using transcranial Doppler in sickle cell anemia: DISPLACE Consortium.  67. 2020
  • Simultaneous osteosarcoma and renal cell carcinoma with BRCA1 mutation in a young male adult with prior oligodendroglioma.  67. 2020
  • Treatment of pediatric high-grade central nervous system tumors with high-dose methotrexate in combination with multiagent chemotherapy: A single-institution experience.  67. 2020
  • Partial response to carboplatin, etoposide phosphate, and atezolizumab in a pediatric patient with high-grade metastatic tumor with rhabdoid and focal neuroendocrine features.  67. 2020
  • Hemophagocytic lymphohistiocytosis in systemic mastocytosis treated with allogeneic bone marrow transplant: A case report..  67:e28017. 2020
  • A unique phenotype of T-cell acute lymphoblastic leukemia in a patient with GATA2 haploinsufficiency.  66. 2019
  • No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy.  66. 2019
  • Outcome for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance).  66. 2019
  • Physical fitness in survivors of childhood Hodgkin lymphoma: A report from the St. Jude Lifetime Cohort.  66. 2019
  • Peripheral blood flow cytometry for the diagnosis of pediatric acute leukemia: Highly reliable with rare exceptions.  66. 2019
  • Significance of CNS 2 cerebrospinal fluid status post-induction in pediatric and adolescent patients with acute lymphoblastic leukemia.  66. 2019
  • Impact of early analgesia on hospitalization outcomes for sickle cell pain crisis.  65. 2018
  • Red blood cell transfusion therapy for sickle cell patients with frequent painful events.  65. 2018
  • Influence of fitness on health status among survivors of acute lymphoblastic leukemia.  65. 2018
  • Outcomes of febrile events in pediatric patients with sickle cell anemia.  65. 2018
  • Acute myelogenous leukemia in adolescents and young adults.  65. 2018
  • Sickle Cell Clinical Research and Intervention Program (SCCRIP): A lifespan cohort study for sickle cell disease progression from the pediatric stage into adulthood.  65. 2018
  • Management of severe chronic pain with methadone in pediatric patients with sickle cell disease.  65. 2018
  • Randomized web-based physical activity intervention in adolescent survivors of childhood cancer.  65. 2018
  • Blinatumomab activity in a patient with Down syndrome B-precursor acute lymphoblastic leukemia.  65. 2018
  • History of parvovirus B19 infection is associated with silent cerebral infarcts.  65. 2018
  • Complete durable response of a pediatric anaplastic oligodendroglioma to temozolomide alone: Case report and review of literature.  64. 2017
  • Characterization of the anti-CD22 targeted therapy, moxetumomab pasudotox, for B-cell precursor acute lymphoblastic leukemia..  64. 2017
  • Integration of ruxolitinib into dose-intensified therapy targeted against a novel JAK2 F694L mutation in B-precursor acute lymphoblastic leukemia..  64. 2017
  • Characteristics and outcomes in children with undifferentiated embryonal sarcoma of the liver: A report from the National Cancer Database.  64. 2017
  • Cranial epidural hematomas: A case series and literature review of this rare complication associated with sickle cell disease.  64. 2017
  • Inferior outcomes for black children with high risk acute lymphoblastic leukemia and the impact of socioeconomic variables.  64:267-274. 2017
  • Elective cholecystectomy reduces morbidity of cholelithiasis in pediatric sickle cell disease.  64:113-120. 2017
  • Metachronous T-Lymphoblastic Lymphoma and Burkitt Lymphoma in a Child With Constitutional Mismatch Repair Deficiency Syndrome.  63:1454-1456. 2016
  • Responsiveness of PROMIS® Pediatric Measures to Hospitalizations for Sickle Pain and Subsequent Recovery.  63:1038-1045. 2016
  • Outcome of Children with Standard-Risk T-Lineage Acute Lymphoblastic Leukemia—Comparison among Different Treatment Strategies.  63:255-261. 2016
  • Subcutaneous panniculitis-like T-cell lymphoma: Pediatric case series demonstrating heterogeneous presentation and option for watchful waiting.  62:2025-2028. 2015
  • 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study.  62:1427-1436. 2015
  • Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology group Study AALL0434.  62:1176-1183. 2015
  • Attack of the cancer-killing viruses: Clinical application of oncolytic virotherapy in children.  62:739-740. 2015
  • SIOP PODC adapted treatment recommendations for standard-risk medulloblastoma in low and middle income settings.  62:553-564. 2015
  • Intensified chemotherapy without SCT in infant ALL: Results from COG P9407 (Cohort 3).  62:419-426. 2015
  • Factors associated with recruiting adult survivors of childhood cancer into clinic-based research.  61:1846-1851. 2014
  • PedsQL™ multidimensional fatigue scale in sickle cell disease: Feasibility, reliability, and validity.  61:171-177. 2014
  • Sirolimus for non-progressive NF1-associated plexiform neurofibromas: An NF clinical trials consortium phase II study.  61:982-986. 2014
  • Pitfalls of using administrative data sets to describe clinical outcomes in sickle cell disease.  60:1936-1939. 2013
  • Neurocognitive and behavioral outcomes in Latino childhood cancer survivors.  60:1696-1702. 2013
  • Relapse after treatment of pediatric hodgkin lymphoma: Outcome and role of surveillance after end of therapy.  60:1458-1463. 2013
  • Exploring barriers and facilitators to clinical trial enrollment in the context of sickle cell anemia and hydroxyurea.  60:1333-1337. 2013
  • PedsQL™ sickle cell disease module: Feasibility, reliability, and validity.  60:1338-1344. 2013
  • Children's Oncology Group's 2013 blueprint for research: Nursing discipline.  60:1031-1036. 2013
  • Children's Oncology Group's 2013 blueprint for research: Survivorship and outcomes.  60:1063-1068. 2013
  • A worldwide collaboration to harmonize guidelines for the long-term follow-up of childhood and young adult cancer survivors: A report from the international late effects of Childhood Cancer Guideline Harmonization Group.  60:543-549. 2013
  • An fMRI investigation of working memory and its relationship with cardiorespiratory fitness in pediatric posterior fossa tumor survivors who received cranial radiation therapy.  60:669-675. 2013
  • Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.  60:396-401. 2013
  • Hydroxyurea treatment of children with hemoglobin SC disease.  60:323-325. 2013
  • CD133 marks a myogenically primitive subpopulation in rhabdomyosarcoma cell lines that are relatively chemoresistant but sensitive to mutant HSV.  60:45-52. 2013
  • Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab.  60:101-109. 2013
  • FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: A report from the Children's Oncology Group.  59:662-667. 2012
  • Influence of severity of anemia on clinical findings in infants with sickle cell anemia: Analyses from the BABY HUG study.  59:675-678. 2012
  • Evaluation of polymorphisms in EWSR1 and risk of Ewing sarcoma: A report from the childhood cancer survivor study.  59:52-56. 2012
  • Sickle cell disease in California: Sociodemographic predictors of emergency department utilization.  58:66-73. 2012
  • Childhood cancer survivorship educational resources in North American pediatric hematology/oncology fellowship training programs: A survey study.  57:1186-1190. 2011
  • Hedgehog pathway activity in pediatric embryonal rhabdomyosarcoma and undifferentiated sarcoma: A report from the Children's Oncology Group.  57:930-938. 2011
  • Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: Results of Children's Oncology Group trial P9906.  57:569-577. 2011
  • Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: A report from the Children's Oncology Group.  57:204-209. 2011
  • Auditory complications in childhood cancer survivors: A report from the childhood cancer survivor study.  57:126-134. 2011
  • Long-term complete response after treatment with cytarabine, vincristine, and prednisone in an infant with refractory multisystem Langerhans cell histiocytosis.  57:180-181. 2011
  • Disparities in cancer outcomes: Lessons learned from children with cancer.  56:994-1002. 2011
  • Sickle-cell disease in California: A population-based description of emergency department utilization.  56:413-419. 2011
  • Complete response to carboplatin, gemcitabine, and paclitaxel in a patient with advanced metastatic renal medullary carcinoma.  55:1217-1220. 2010
  • Treatment of primary CNS lymphoma with high-dose methotrexate in immunocompetent pediatric patients.  55:1227-1230. 2010
  • Sirolimus therapy for fibromatosis and multifocal renal cell carcinoma in a child with tuberous sclerosis complex.  54:1035-1037. 2010
  • Ocular late effects in childhood and adolescent cancer survivors: A report from the childhood cancer survivor study.  54:103-109. 2010
  • Lymphocytic vasculitis involving the central nervous system occurs in patients with X-linked lymphoproliferative disease in the absence of Epstein-Barr virus infection.  53:1120-1123. 2009
  • Myelofibrosis in a patient with familial hemophagocytic lymphohistiocytosis.  50:1260-1262. 2008
  • Changing trends of research and treatment in infant neuroblastoma.  49:1060-1065. 2007
  • Assessment of health-related quality of life of adolescent cancer patients using the minneapolis-manchester quality of life adolescent questionnaire.  48:678-686. 2007
  • Long-term follow-up of childhood cancer survivors: Future directions for clinical care and research.  46:143-148. 2006
  • Long-term follow-up of pediatric cancer survivors: Education, surveillance, and screening.  46:149-158. 2006
  • Early molecular detection of central nervous system relapse in a child with systemic anaplastic large cell lymphoma: Case report and review of the literature.  44:400-406. 2005
  • Family history of cancer in children and young adults with colorectal cancer.  33:470-475. 1999
  • Family history of cancer in children and young adults with colorectal cancer..  33:470-475. 1999
  • Langerhans cell histiocytosis: An exploratory epidemiologic study of 177 cases.  28:92-97. 1997
  • Arteriovenous malformation mimicking recurrent medulloblastoma.  22:140-143. 1994
  • Management of pineal non‐germinoma germ cell tumor with residual teratoma and normal alpha‐fetoprotein.  22:137-139. 1994
  • Alveolar rhabdomyosarcoma with the t(2;13): Cytogenetic findings and clinicopathologic correlations.  21:83-87. 1993
  • Comparison of serial PET and MRI scans in a pediatric patient with a brainstem glioma.  21:301-306. 1993
  • False‐positive MRI detection of recurrent or metastatic pediatric infratentorial tumors.  21:350-355. 1993
  • Reversal of radiation‐induced neutropenia by granulocyte colony‐stimulating factor.  20:240-242. 1992
  • Osteoblastic metastases from astrocytomas: A report of two cases.  19:318-324. 1991
  • Reversible neurotoxicity following hyperfractionated radiation therapy of brain stem glioma.  19:182-186. 1991
  • Selection of a management strategy for pediatric brainstem tumors.  17:116-125. 1989
  • Selection of a management strategy for pediatric brainstem tumors..  17:117-126. 1989
  • Phase II evaluation of chlorozotocin in metastatic sarcomas.  12:25-27. 1984
  • Adriamycin, BCNU, and cyclophosphamide in drug‐resistant adenocarcinoma of the ovary.  11:151-153. 1983
  • A prospective study of histocompatible leukocyte and platelet transfusions during induction chemotherapy of adult acute nonlymphocytic leukemia.  9:225-234. 1981
  • Successful chemotherapy for childhood metastatic embryonal cell carcinoma of the testicle: A preliminary report.  8:75-81. 1980
  • International Standard Serial Number (issn)

  • 0098-1532
  • 1545-5009
  • Electronic International Standard Serial Number (eissn)

  • 1096-911X
  • 1545-5017